« Previous
Next »
Titles
- A comparison of brand-name drug prices among selected federal programs1
- A public option for health insurance in the nongroup marketplaces: key design considerations and implications1
- ACF cannot ensure that all child victims of abuse and neglect have court representation1
- ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of rDNA origin1
- Arthroscopy pump tubing sets intended for multiple patient use - Premarket Notification (510(k)) submissions: guidance for industry and Food and Drug Administration staff1
- Associations between county-level vaccination rates and COVID-19 outcomes among Medicare beneficiaries2
- Availability of supplemental benefits in Medicare Advantage plans in rural and urban areas1
- Awake fiber optic intubation1
- BPC’s key considerations for developing a Medicaid home and community-based services benefit1
- Behavioral health and COVID-19: higher-risk populations and related federal relief funding : report to congressional committees1
- Biomedical research: information on federal contributions to remdesivir : report to Congressional addressees1
- Bipartisan solutions to improve the availability of long-term care1
- Bispecific antibody development programs1
- Black Lung benefits program: continued inaction on coal operator self-insurance increases financial risk to trust fund : testimony before the Committee on Education and Labor, Subcommittee on Workforce Protections, House of Representatives1
- Bridging health and health care1
- CBO's model of drug price negotiations under the Elijah E. Cummings Lower Drug Costs Now Act1
- CBO's simulation model of new drug development1
- CMC postapproval manufacturing changes for specified biological products to be documented in annual reports2
- CMS could improve the data it uses to monitor antipsychotic drugs in nursing homes1
- CMS use of data on nursing home staffing: progress and opportunities to do more1